国际版

中国

法国

俄罗斯

印度尼西亚

土耳其

印度

越南

西班牙

巴西和葡萄牙

Privacy Policy

Terms & Conditions

实时赛事

体育

电子竞技

锦标赛

足球

篮球

网球

板球

所有促销活动

体育欢迎奖金

赌场欢迎奖金

每周返现

体育俱乐部

VIP 俱乐部

联盟计划

加密货币博彩

简介

我的投注

我的奖金

设置

投注池

排行榜

预测

学院

帮助中心

文档

关于

代币

职业机会

联系我们

品牌资源

周边商品

添加币种与网络

负责任博彩

OG.Dexsport

大厅

真人赌场

崩盘游戏

桌面游戏

老虎机游戏

购买奖金

轮盘赌

服务提供商

当前热门

赌场

首页

This market will resolve to "Yes" if a natural meteoroid (bolide) explodes in Earth's atmosphere with a total impact energy greater than or equal to 1 megaton (1000 kilotons) of TNT equivalent between January 1 and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.

The object must be classified as a natural meteoroid; events involving artificial objects or reentry vehicles do not qualify.

The primary resolution source will be the NASA JPL Fireball and Bolide Data repository: https://cneos.jpl.nasa.gov/fireballs/. The relevant field for determining impact energy is the “Impact Energy (kt)” column. If this dataset has not been updated to include all relevant dates by February 28, 2027, or if the NASA JPL Fireball and Bolide Data repository becomes permanently unavailable, this market may resolve based on a consensus of credible sources including the European Space Agency (ESA), the International Asteroid Warning Network (IAWN), the U.S. Department of Defense, or credible reporting of a scientific consensus, such as a NASA press release.

1 megaton meteor strike in 2026?

2026年有1百万吨流星撞击？

This market will resolve to "Yes" if Microsoft officially releases Project Helix by the listed date, 11:59 PM ET. Otherwise, this market will resolve to "No".

A qualifying product must be acknowledged to be part of Project Helix and be recognized as a major Xbox console, similar to the Xbox Series X or Xbox One. A new Xbox console not acknowledged by Microsoft as being part of Project Helix will not qualify.

In order to be considered released, the product must be available for purchase by the general public within the specified timeframe. An announcement or unveiling alone is not sufficient.

The primary resolution source for this market will be official statements from Microsoft. However, a consensus of credible reporting may also be used.

December 31, 2026

May 31, 2027

When will Project Helix be released?

Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

FDA approves Retatrutide this year?

FDA今年批准Retatrutide ？

This market will resolve to “Yes” if the upper bound of the target federal funds rate is increased at any point between December 16, 2025 and the completion of the listed Federal Open Market Committee (FOMC) meeting (inclusive of any rate hike announced as a result of the listed meeting). Otherwise, this market will resolve to “No”.

If the listed meeting does not take place within 7 calendar days (ET) of its scheduled end date, 11:59 PM ET, and no qualifying rate cut has been announced, this market will resolve to "No".

Emergency rate hikes will qualify.

The primary resolution source for this market will be the official website of the Federal Reserve (https://www.federalreserve.gov/monetarypolicy/openmarket.htm), however a consensus of credible reporting may also be used.

美联储加息... ？

市场概况

热门动态

时间轴

活动

热门动态

平台

体育博彩

赌场

促销活动

资源

服务